Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 4/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7463647 | 0.86 | F2 (0.42) | CCR4F2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7156977 | 0.85 | F2 (0.43) | CCR4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL7102590 | 0.82 | ST14 (0.40) | CCR4F2ACEACE2MEN1 | |
| SCHEMBL7105056 | 0.82 | F2 (0.46) | F2 | |
| SCHEMBL7102491 | 0.82 | F2 (0.42) | CCR4F2ACENPSR1 | |
| SCHEMBL7106036 | 0.82 | F2 (0.53) | F2NPSR1 | |
| Hydrochloric Acid SCHEMBL7140906 | 0.81 | F2 (0.54) | F2 | |
| SCHEMBL7363339 | 0.81 | TMPRSS11D (0.49) | F2 | |
| Hydrochloric Acid SCHEMBL7156980 | 0.80 | TMPRSS11D (0.49) | F2 | |
| SCHEMBL7363788 | 0.77 | TMPRSS11D (0.45) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010018423-A1 | Anticoagulant agents | KLIMKOWSKI VALENTINE J (US) | 2001-08-30 | — | — | US | claimed |
| WO-1997049404-A1 | ANTICOAGULANT AGENTS | ELI LILLY AND COMPANY (US) | 1997-12-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018423-A1 | Anticoagulant agents | SERPINC1, F12, F11 | CCR4 2229/4885F2 4/4885OPRM1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.